CS Barasa Announces Second Mpox Case
Health Cabinet Secretary Deborah Barasa has confirmed that Kenya has recorded its second case of Mpox.
The case was confirmed after samples were taken from a male truck driver at the Malaba One Stop Border post in Busia who had exhibited signs of the disease.
Upon conducting the tests, laboratory results, she noted, turned positive for the disease.
“The Ministry wishes to inform the public of a second laboratory-confirmed case of the disease in the country; an adult male truck driver who presented to the Port Health screening desk at the Malaba One Stop Border Post- Busia County with salient symptoms of the disease and a history of travel to the epicenter of the outbreak in DRC,” CS Barasa said.
The CS said the patient has been isolated and is under active management in one of our health facilities in Busia County.
ALSO READ:
- From Diallo to Guirassy: Season’s best African players
- “From Missing to Messy: Juja MP Koimburi Accused of Orchestrating Own Disappearance”
- Unity for Progress: Raila Offers Land for Affordable Homes in Kisumu
- Wamunyoro, From Quiet Village to Kenya’s New Political Powerhouse
- SHOCKING CONFESSION- Museveni and First Lady BEG for Forgiveness After 39 Years of MISTAKES AND BETRAYAL
She added that active surveillance for suspected cases has been enhanced in the region and across all counties to ensure the spread of the disease is controlled.
To date, the CS said a total of forty-two (42) samples have been submitted to laboratories for Mpox disease testing out of which forty (40) samples have tested negative for the disease.
In addition, CS Barasa added that they have screened a total of 426,438 travelers at various Ports of Entry across the country.
“The Ministry emphasizes that our health facilities are adequately staffed and well-equipped to diagnose and manage this disease and therefore its identification should not be a cause for alarm,” she said.
Since the declaration of the first case on July 31, 2024, at least 28 contacts of the said case have completed a 21-day follow-up period without developing symptoms and have been discharged from active follow-up.
CS Barasa Announces Second Mpox Case
